|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Baseline phase** | **Research Phase** | | | | | | | | | | | **End** |
| **TIMEPOINT** | **D0** | **D1** | **D2** | **D3** | **D4** | **D5** | **D6** | **D7** | **D…** | **D10** | **D…** | **D14** | **D28** |
| **Inclusion and grouping** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Screening cases | X |  |  |  |  |  |  |  |  |  |  |  |  |
| Informed consent | X |  |  |  |  |  |  |  |  |  |  |  |  |
| Inclusion group | X |  |  |  |  |  |  |  |  |  |  |  |  |
| Baseline data collection | X |  |  |  |  |  |  |  |  |  |  |  |  |
| **Drug-assisted therapy** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Develop a Dosing Plan | X |  |  |  |  |  |  |  |  |  |  |  |  |
| Assess drug-related adverse reactions |  | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** |
| Evaluation of serious adverse events |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Clinical and laboratory data collection** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Vital signs | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** | **X** |
| SOFA score | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Arterial blood gas analysis | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Blood routine | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Coagulation index | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Inflammatory factors | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Liver and kidney function | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| CRP | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| PCT | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Muscle enzyme + myoglobin | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  |
| Throat swab nucleic acid | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** | **X** |  | **X** |  |
| ECG | **X** |  |  |  |  | **X** |  |  |  |  |  |  |  |
| Chloroquine blood concentration | **X** | **X** |  | **X** |  | **X** |  | **X** |  | **X** |  | **X** | **X** |

**Table 1 The schedule of treatment visits and data collection.**

The SOFA(Sequential Organ Failure Assessment) score , predicts mortality risk for patients in the intensive care unit based on lab results and clinical data.1

Inflammatory factors: Various cytokines involved in inflammation, such as IL-6, IL-10, TNF-α, etc.

Liver function: Blood indicators reflecting liver function, such as alanine aminotransferase, aspartate aminotransferase, etc.

Kidney function: Blood indicators reflecting kidney function, such as blood urea nitrogen, blood creatinine, etc.

PCT(procalcitonin): A protein who increases when severe bacterial, fungal, and parasitic infections, sepsis, and multiple organ failure occur.

D0: Before the research; D1: The 1st day of the research; D2: The 2nd day of the research; D3: The 3rd day of the research; D4: The 4th day of the research; D5: The 5th day of the research; D6: The 6th day of the research; D7: The 7th day of the research; D10: The 10th day of the research; D14: The 14th day of the research; D28: The 28th day of the research.

**References:**

1 Medlej K. Calculated decisions: sequential organ failure assessment (SOFA) score. *Emerg Med Pract* 2018;20:CD1-CD2.